Anti-VEGF (specialist intravitreal)
Brolucizumab
Brand names: Beovu
Adult dose
Dose: 6mg intravitreal — 3 monthly loading then q8–12w per response
Route: Intravitreal
Frequency: q8–12w (after loading)
Clinical pearls
- NICE TA672: nAMD; TA820: DMO
- RCOphth — MHRA Drug Safety Update on intraocular inflammation; vigilance for sudden visual loss
- Specialist ophthalmology
Contraindications
- Ocular/periocular infection
- Active intraocular inflammation
- Hypersensitivity
Side effects
- Intraocular inflammation / vasculitis / occlusive retinal vasculitis (signal — MHRA)
- Endophthalmitis
- Increased IOP
- Cataract
- Vitreous haemorrhage
Monitoring
- Visual acuity
- OCT
- IOP
- Inflammation signs
Reference: BNF; NICE TA672; NICE TA820; RCOphth; MHRA Drug Safety Update; SmPC; https://bnf.nice.org.uk/drugs/brolucizumab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme